Immune cell therapy for early-stage multiple lung cancers
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a treatment using your own immune cells (called TILs) to fight multiple early-stage lung cancers. The cells are collected from a tumor sample, grown in a lab, and given back to you to help your body attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have multiple lung nodules that have been present for at least a year and are diagnosed as lung cancer by a team of doctors.
- You have had surgery for non-small cell lung cancer, but the cancer has come back or new nodules have appeared, and you do not want surgery or other treatments.
- You can provide a tumor sample (about the size of a small marble) through surgery, biopsy, or bronchoscopy.
- You are generally healthy enough for this treatment, with adequate blood counts and organ function.
- You are not currently taking steroids, have no severe infections, autoimmune diseases, or active hepatitis, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer that has progressed after standard therapy. You would have surgery to collect a tumor sample, then receive your expanded immune cells back as an infusion.
This trial tests a new treatment using your own immune cells (called TILs) to fight advanced non-small cell lung cancer. The cells are taken from a tumor, multiplied in a lab, and given back to you to help your body attack the cancer.
This trial tests a new treatment for advanced non-small cell lung cancer that has stopped responding to a targeted pill (EGFR-TKI). It combines your own immune cells, grown in a lab, with another targeted pill to try to fight the cancer.
This trial tests a new cell therapy that uses your own immune cells (TILs) to fight lung cancer. If you have advanced non-small cell lung cancer and standard treatments haven't worked, this treatment might help your immune system attack the cancer more effectively.
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
This trial tests a type of immune cell treatment called TIL (tumor-infiltrating lymphocytes) in people with advanced solid cancers. It may help your immune system better recognize and attack tumors, especially if standard treatments have not worked.
Hear when a new Primary Early-stage Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.